Tofogliflozin decreases body fat mass and improves peripheral insulin resistance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance

Published:2018-05 Issue:5 Volume:20 Page:1311-1315
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Matsuba Ren¹^ORCID,Matsuba Ikuro²,Shimokawa Mototsugu³,Nagai Yoshio¹,Tanaka Yasushi¹

Affiliation:

1. Department of Internal Medicine, Division of Metabolism and EndocrinologySt Marianna University School of Medicine Kanagawa Japan

2. Matsuba Medical Clinic Kanagawa Japan

3. Department of Cancer Information Research, National Kyushu Cancer CenterClinical Research Institute Fukuoka Japan

Funder

Kowa Company Ltd

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13211

Reference17 articles.

1. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

2. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus

3. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial

4. Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes

5. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07-08

2. Assessing the Metabolic and Physical Effects of Combined DPP4 and SGLT2 Inhibitor Therapy in Patients with Type-2 Diabetes Mellitus: An Observational Prospective Pilot Study;JMA Journal;2024

3. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved;Clinical Nutrition;2023-12

4. Current Nutritional and Pharmacological Approaches for Attenuating Sarcopenia;Cells;2023-10-09

5. Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment;Nutrients;2023-09-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3